Clinical Evaluation of a Test for Monitoring the Recurrence of Bladder Cancer

Completed

Conditions studied: Bladder Cancer

In brief

The objective of this study is to establish the performance characteristics of an assay that detects the recurrence of bladder cancer in patients previously diagnosed with bladder cancer. The study is conducted at locations within and outside of the United States. Testing is performed on urine specimens provided by eligible enrolled patients. Results from this study will not be used for patient management decisions.

Key facts

Study ID

NCT03125460

Run by

Cepheid

People needed

424

Starts

2016-12-01

Expected to finish

2019-05-01

Last updated by the study team

2020-02-07

Who can join

Age: 40 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject is ≥ 40 years of age
• Subject has provided documented informed consent as required by the reviewing IRB or EC. Experimental Bill of Rights will be documented for all subjects enrolled in applicable states.
• Subject is considered disease positive within 12 months (365 days) of enrollment.
• At the time of the enrollment visit, the subject is scheduled for a standard of care cystoscopy which will be completed within 3 days of providing a urine specimen.
• Subject has agreed to provide at least 60 mL of voided urine for study purposes at the enrollment visit.
• Subject has agreed to provide at least 60 mL of voided urine for study purposes at each subsequent standard of care cystoscopy visit for at least 12 months (365 days) following enrollment if the subject will enter the Longitudinal cohort.
• Any subject considered anticipatory positive at the initial visit shall be enrolled into the longitudinal cohort. For each anticipatory positive enrolled into the longitudinal cohort a random disease negative subject shall be enrolled.
• Exclusion
• Subject has been previously enrolled into the study.
• Urine specimen to be used for study purposes is from the first morning void.
• Subject has had an excision procedure within six weeks (42 days) of enrollment.
• The subject is not scheduled for a standard of care cystoscopy visit within 12 months (365 days) following enrollment.

Where it is running

• PAVA — Palo Alto, California, United States
• The Urology Center of Colorado, P.C. — Denver, Colorado, United States
• Urology Associates, P.C. — Englewood, Colorado, United States
• North Idaho Urology — Coeur d'Alene, Idaho, United States
• Idaho Urologic Institute — Meridian, Idaho, United States
• UroPartners — Melrose Park, Illinois, United States
• Five Valleys Urology — Missoula, Montana, United States
• Weill Cornell Medicine — New York, New York, United States
• Stephenson Cancer Center — Oklahoma City, Oklahoma, United States
• UT Southwestern — Dallas, Texas, United States
• Virginia Urology — Richmond, Virginia, United States
• The Male/Female Health and Research Centre — Barrie, Ontario, Canada
• G Kenneth Jansz Medicine Professional Corp. — Burlington, Ontario, Canada
• Urology Associates / Urologic Medical Research — Kitchener, Ontario, Canada
• Urology Clinic of Dr. Goldfarb — North Bay, Ontario, Canada
• Urologic Clinic of Stanley Flax — North York, Ontario, Canada
• Radboud University Medical Center — Nijmegen, Netherlands

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.